Effect of lacosamide on structural damage and functional recovery after traumatic brain injury in rats

Epilepsy Research

Volumn 108, Issue 4, 2014, Pages 653-665

  Pitkanen A ^a,b   Immonen, R ^a   Ndode Ekane, X ^a   Grohn O ^a   Stohr T ^c,d   Nissinen, J ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Schwarz BioSciences GmbH (a member of the UCB group)   (Germany)

^d A2M Pharma GmbH   (Germany)

Author keywords

Antiepileptic drug; Lateral fluid percussion; Magnetic resonance imaging; Neurodegeneration

Indexed keywords

HARKOSERIDE; ACETAMIDE DERIVATIVE; ANTICONVULSIVE AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; BRAIN CORTEX; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; HIPPOCAMPUS; HISTOPATHOLOGY; INJURY SEVERITY; LATENT PERIOD; MALE; MENTAL CAPACITY; MORRIS WATER MAZE TEST; MOTOR PERFORMANCE; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; ANIMAL; BRAIN; BRAIN INJURIES; DISEASE MODEL; DRUG EFFECTS; MAZE TEST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; BRAIN; BRAIN INJURIES; DISEASE MODELS, ANIMAL; MALE; MAZE LEARNING; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION;

EID: 84897973901     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2014.02.001     Document Type: Article

References (51)

1. Belayev L., Alonso O.F., Liu Y., Chappell A.S., Zhao W., Ginsberg M.D., Busto R. Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats. J. Neurotrauma 2001, 18(10):1031-1038.
2. Beyreuther B.K., Freitag J., Heers C., Krebsfänger N., Scharfenecker U., Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007, 13(1):21-42.
3. Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation Practice parameter: antiepileptic drug treatment of posttraumatic seizures. Arch. Phys. Med. Rehabil. 1998, 79(5):594-597.
4. Chan K.H., Tharakan J., Pal H.K., Khan N., Tan Y.C. Risk factors and phenytoin prophylaxis for early post-traumatic seizures among patients with traumatic brain injury. Malays. J. Med. Sci. 2010, 17(4):36-43.
5. Childers M.K., Holland D. Psychomotor agitation following gabapentin use in brain injury. Brain Inj. 1997, 11(7):537-540.
6. Cole J.T., Yarnell A., Kean W.S., Gold E., Lewis B., Ren M., McMullen D.C., Jacobowitz D.M., Pollard H.B., O'Neill J.T., Grunberg N.E., Dalgard C.L., Frank J.A., Watson W.D. Craniotomy: true sham for traumatic brain injury, or a sham of a sham?. J. Neurotrauma 2011, 28(3):359-369.
7. Cross S.A., Curran M.P. Lacosamide: in partial-onset seizures. Drugs 2009, 69(4):449-459.
8. Darrah S.D., Chuang J., Mohler L.M., Chen X., Cummings E.E., Burnett T., Reyes-Littaua M.C., Galang G.N., Wagner A.K. Dilantin therapy in an experimental model of traumatic brain injury: effects of limited versus daily treatment on neurological and behavioral recovery. J. Neurotrauma 2011, 28(1):43-55.
9. Dash P.K., Orsi S.A., Zhang M., Grill R.J., Pati S., Zhao J., Moore A.N. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS ONE 2010, 5(6):e11383.
10. Debenham S., Sabit B., Saluja R.S., Lamoureux J., Bajsarowicz P., Maleki M., Marcoux J. A critical look at phenytoin use for early post-traumatic seizure prophylaxis. Can. J. Neurol. Sci. 2011, 38(6):896-901.
11. Errington A.C., Stöhr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 2008, 73(1):157-169.
12. Freund T.F., Ylinen A., Miettinen R., Pitkänen A., Lahtinen H., Baimbridge K.G., Riekkinen P.J. Pattern of neuronal death in the rat hippocampus after status epilepticus: relationship to calcium binding protein content and ischemic vulnerability. Brain Res. Bull. 1992, 28(1):27-38.
13. Geis C., Beyreuther B.K., Stöhr T., Sommer C. Lacosamide has protective disease modifying properties in experimental vincristine neuropathy. Neuropharmacology 2011, 61(4):600-607.
14. Halonen T., Nissinen J., Jansen J.A., Pitkänen A. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur. J. Pharmacol. 1996, 299(1-3):69-81.
15. Han M.H., Craig S.B., Rutner D., Kapoor N., Ciuffreda K.J., Suchoff I.B. Medications prescribed to brain injury patients: a retrospective analysis. Optometry 2008, 79(5):252-258.
16. Hernandez T.D. Preventing post-traumatic epilepsy after brain injury: weighing the costs and benefits of anticonvulsant prophylaxis. Trends Pharmacol. Sci. 1997, 18(2):59-62.
17. Hoover R.C., Motta M., Davis J., Saatman K.E., Fujimoto S.T., Thompson H.J., Stover J.F., Dichter M.A., Twyman R., White H.S., McIntosh T.K. Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats. J Neurotrauma 2004, 21(5):501-512.
18. Ivanhoe C.B., Hartman E.T. Clinical caveats on medical assessment and treatment of pain after TBI. J. Head Trauma Rehabil. 2004, 19(1):29-39.
19. Jones K.E., Puccio A.M., Harshman K.J., Falcione B., Benedict N., Jankowitz B.T., Stippler M., Fischer M., Sauber-Schatz E.K., Fabio A., Darby J.M., Okonkwo D.O. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg. Focus 2008, 25(4):E3.
20. Keck C.A., Thompson H.J., Pitkänen A., LeBold D.G., Morales D.M., Plevy J.B., Puri R., Zhao B., Dichter M., McIntosh T.K. The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury. Restor. Neurol. Neurosci. 2007, 25(2):77-90.
21. Koo T.S., Kim S.J., Ha D.J., Baek M., Moon H. Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats. Arch. Pharm. Res. 2011, 34(12):2059-2064.
22. Liesemer K., Bratton S.L., Zebrack C.M., Brockmeyer D., Statler K.D. Early post-traumatic seizures in moderate to severe pediatric traumatic brain injury: rates, risk factors, and clinical features. J. Neurotrauma 2011, 28(5):755-762.
23. Ma C.Y., Xue Y.J., Li M., Zhang Y., Li G.Z. Sodium valproate for prevention of early posttraumatic seizures. Chin. J. Traumatol. 2010, 13(5):293-296.
24. McIntosh T.K., Vink R., Noble L., Yamakami I., Fernyak S., Soares H., Faden A.L. Traumatic brain injury in the rat: characterization of a lateral fluid-percussion model. Neuroscience 1989, 28(1):233-244.
25. Montañez S., Kline A.E., Selwyn A.P., Suozzi J.C., Butler S.E., Hernandez T.D. Vigabatrin directed against kindled seizures following cortical insult: impact on epileptogenesis and somatosensory recovery. J. Neurotrauma 2001, 18(11):1255-1266.
26. Narkilahti S., Pirttilä T.J., Lukasiuk K., Tuunanen J., Pitkänen A. Expression and activation of caspase 3 following status epilepticus in the rat. Eur. J. Neurosci. 2003, 18(6):1486-1496.
27. Ndode-Ekane X.E., Pitkänen A. Urokinase-type plasminogen activator receptor modulates epileptogenesis in mouse model of temporal lobe epilepsy. Mol. Neurobiol. 2013, 47(3):914-937.
28. Noguchi K., Gel Y.R., Brunner E., Konietschke F. nparLD: an R software package for the nonparametric analysis for longitudinal data in factorial experiments. J. Stat. Softw. 2012, 50(12):1-23.
29. Ohlsson A.L., Johansson B.B. Environment influences functional outcome of cerebral infarction in rats. Stroke 1995, 26(4):644-649.
30. Pachet A., Friesen S., Winkelaar D., Gray S. Beneficial behavioural effects of lamotrigine in traumatic brain injury. Brain Inj. 2003, 17(8):715-722.
31. Pangilinan P.H., Giacoletti-Argento A., Shellhaas R., Hurvitz E.A., Hornyak J.E. Neuropharmacology in pediatric brain injury: a review. PM & R 2010, 2(12):1127-1140.
32. Park K.D., Morieux P., Salomé C., Cotton S.W., Reamtong O., Eyers C., Gaskell S.J., Stables J.P., Liu R., Kohn H. Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors. J. Med. Chem. 2009, 52(21):6897-6911.
33. Patil V.K., St Andre J.R., Crisan E., Smith B.M., Evans C.T., Steiner M.L., Pape T.L. Prevalence and treatment of headaches in veterans with mild traumatic brain injury. Headache 2011, 51(7):1112-1121.
34. Pitkänen A., Kubova H. Antiepileptic drugs in neuroprotection. Expert Opin. Pharmacother. 2004, 5(4):777-798.
35. Pitkänen A. Neuroprotection with antiepileptic drugs - state of evidence. Seizure Freedom: Clinical, Research and Quality of Life Perspectives 2007, 9-27. Clarion Press, UK. M. Trimble (Ed.).
36. Schallert T., Hernandez T.D., Barth T.M. Recovery of function after brain damage: severe and chronic disruption by diazepam. Brain Res. 1986, 379(1):104-111.
37. Sheets P.L., Heers C., Stoehr T., Cummins T.R. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide[(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 2008, 326(1):89-99.
38. Sherman K.B., Goldberg M., Bell K.R. Traumatic brain injury and pain. Phys. Med. Rehabil. Clin. N. Am. 2006, 17(2):473-490.
39. Smith D.H., Perri B.R., Raghupathi R., Saatman K.E., McIntosh T.K. Remacemide hydrochloride reduces cortical lesion volume following brain trauma in the rat. Neurosci. Lett. 1997, 231(3):135-138.
40. Steinbaugh L.A., Lindsell C.J., Shutter L.A., Szaflarski J.P. Initial EEG predicts outcomes in a trial of levetiracetam vs fosphenytoin for seizure prevention. Epilepsy Behav. 2012, 23(3):280-284.
41. Stöhr T., Kupferberg H.J., Stables J.P., Choi D., Harris R.H., Kohn H., Walton N., White H.S. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 2007, 74(2-3):147-154.
42. Temkin N.R. Preventing and treating posttraumatic seizures: the human experience. Epilepsia 2009, 50(suppl. 2):10-13.
43. Thompson H.J., Lifshitz J., Marklund N., Grady M.S., Graham D.I., Hovda D.A., McIntosh T.K. Lateral fluid percussion brain injury: a 15-year review and evaluation. J. Neurotrauma 2005, 22(1):42-75.
44. + currents. Epilepsia 2012, 53(11):1959-1967.
45. Wang H.C., Chang W.N., Chang H.W., Ho J.T., Yang T.M., Lin W.C., Chuang Y.C., Lu C.H. Factors predictive of outcome in posttraumatic seizures. J. Trauma 2008, 64(4):883-888.
46. Wang Y., Brittain J.M., Jarecki B.W., Park K.D., Wilson S.M., Wang B., Hale R., Meroueh S.O., Cummins T.R., Khanna R. In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation. J. Biol. Chem. 2010, 285(33):25296-25307.
47. Wang B., Dawson H., Wang H., Kernagis D., Kolls B.J., Yao L., Laskowitz D.T. Lacosamide improves outcome in a murine model of traumatic brain injury. Neurocrit. Care 2013, 19(1):125-134.
48. Wilson S.M., Xiong W., Wang Y., Ping X., Head J.D., Brittain J.M., Gagare P.D., Ramachandran P.V., Jin X., Khanna R. Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization. Neuroscience 2012, 210:451-466.
49. Wolff C., Carrington B., Varrin-Doyer M., Vandendriessche A., Van der Perren C., Famelart M., Gillard M., Foerch P., Rogemond V., Honnorat J., Lawson A., Miller K. Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2). CNS Neurosci. Ther. 2012, 18(6):493-500.
50. Yasseen B., Colantonio A., Ratcliff G. Prescription medication use in persons many years following traumatic brain injury. Brain Inj. 2008, 22(10):752-757.
51. Zaccara G., Perucca P., Loiacono G., Giovannelli F., Verrotti A. The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2013, 54(1):66-74.